Alpine Immune Sciences Competitors, Revenue, Alternatives and Pricing

Claim your profile

Overview

Location:
Seattle, WA USA
Total Funding:$52.6M
Industry:Biotech
Founded:2015
Lead Investor(s):OrbiMed Advisors

Industry Ranking

Estimated Revenue & Financials

  • Alpine Immune Sciences's estimated annual revenue is currently $6.8M per year.
  • Alpine Immune Sciences received $48.0M in venture funding in June 2016.
  • Alpine Immune Sciences's estimated revenue per employee is $117,586
  • Alpine Immune Sciences's total funding is $52.6M.

Employee Data

  • Alpine Immune Sciences has 58 Employees.
  • Alpine Immune Sciences grew their employee count by 18% last year.
  • Alpine Immune Sciences currently has 1 job openings.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingOnline ReviewPricing
#1
$6.4M41193%N/A-N/A
#2
$24.2M156N/AN/A-N/A
#3
$19.2M124N/AN/A-N/A
#4
$19.2M124N/AN/A-N/A
#5
$16.1M104N/AN/A-N/A
#6
$14.3M92-14%N/A-N/A
#7
$11.2M72-31%N/A-N/A
#8
$6.8M5818%N/A-N/A
#9
N/A41N/AN/A-N/A
#10
N/A15N/AN/A-N/A
Missing a competitor? Contribute!?
Submit

Founded in 2015 by a team responsible for the FDA's approval of the world's first cancer immunotherapy and experts in the field of recombinant protein based immunotherapies, Alpine Immune Sciences was created to capitalize on our unique understanding of immunology, modifying the complexities of the immune synapse for the benefit of patients living with cancer, autoimmune disorders, and other diseases. Traded on NASDAQ under ticker ALPN.

keywords:Biotechnology,Healthcare,Pharmaceuticals

58

Number of Employees

$6.8M

Revenue (est)

1

Current Jobs

18%

Employee Growth %

$52.6M

Total Funding

N/A

Valuation

N/A

Accelerator

N/A

Type

Alpine Immune Sciences News

09/03/2019 - Alpine Immune Sciences Provides Pipeline Update and ...

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on ...

09/08/2019 - Is Alpine Immune Sciences (NASDAQ:ALPN) Weighed On By Its Debt Load?

We can see that Alpine Immune Sciences, Inc. (NASDAQ:ALPN) does use debt in its business. But should shareholders be worried about its ...

09/03/2019 - Form 8-K ALPINE IMMUNE SCIENCES, For: Aug 13

On August 13, 2019, Alpine Immune Sciences, Inc. issued a press release reporting its financial results for the second quarter of 2019. A copy ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal FundingOnline ReviewPricing
#1
$14.7M587%N/A-N/A
#2
N/A58N/AN/A-N/A
#3
$14.2M58N/AN/A-N/A
#4
N/A582%N/A-N/A
#5
$6.2M5857%N/A-N/A

Alpine Immune Sciences Funding

DateAmountRoundLead InvestorsReference
2016-06-14$48.0MAOrbiMed AdvisorsArticle

Alpine Immune Sciences Executive Hires

DateNameTitleReference
2016-06-14Mitchell H. GoldExecutive Chairman/acting Chief Executive OfficerArticle
2016-09-16Stanford PengEVP/CMOArticle
2018-08-07Mark LittoPresident & COOArticle

Alpine Immune Sciences Acquisitions

DateCompany NameAmountNotesReference
2017-07-27Nivalis Therapeutics, IncComplete - Cash in dealArticle